Walleye Capital
RLMD icon

Walleye Capital’s Relmada Therapeutics RLMD Stock Holding History

Walleye Capital’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.26M Buy
+616,238
New +$4.31M 0.02% 924
2023
Q2 		– Sell
-262,481
Closed -$593K – 4808
2023
Q1 		$593K Sell
262,481
-211,202
-45% -$728K 0.01% 1573
2022
Q4 		$1.65M Buy
+473,683
New +$4.16M 0.03% 686
2022
Q3 		– Sell
-106,420
Closed -$2.95M – 3491
2022
Q2 		$2.02M Sell
106,420
-16,809
-14% -$367K 0.06% 362
2022
Q1 		$3.33M Buy
123,229
+102,410
+492% +$2.12M 0.09% 236
2021
Q4 		$469K Buy
+20,819
New +$463K 0.01% 1027

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Walleye Capital's RLMD Position: Q2 2026 in Review

Walleye Capital opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 616,238 shares worth $4.26M. The stake represents 0.02% of the portfolio and ranks #924 among its holdings. This is a return to the name: Walleye Capital previously reported a position in RLMD as recently as Q1 2023.

Walleye Capital first reported a position in RLMD in Q4 2021 and has held it in 6 quarters since. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Walleye Capital held 616,238 shares of Relmada Therapeutics worth $4.26M as of Q2 2026.
  • Relmada Therapeutics was a new Walleye Capital position in Q2 2026.
  • Relmada Therapeutics made up 0.02% of Walleye Capital's portfolio in Q2 2026, its #924 holding.
  • Walleye Capital first reported a position in Relmada Therapeutics in Q4 2021 and has held it in 6 quarters since.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.